GlassScriptPhysician profile
Chetan K Shah
NPI 1518971936
$4,138.11
in general payments reported to CMS, 2019-2025
28 companies · $681 in 2025
The $681 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $178 · 2021: $606 · 2022: $743 · 2023: $1,071 · 2024: $619 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,313 · Education: $58.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,313.00 |
| Education | $58.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $660.87 | 2019-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $515.93 | 2019-2023 | Veltassa |
| Amgen INC. | $392.92 | 2021-2025 | Krystexxa, Uplizna |
| Ani Pharmaceuticals, INC. | $325.09 | 2023-2025 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $301.77 | 2019-2025 | Rayaldee |
| Sanofi-Aventis U.S. LLC | $198.22 | 2022 | |
| Mozarc Medical US LLC | $168.98 | 2024-2025 | Argyle |
| Shockwave Medical, INC | $155.00 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.61 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $136.75 | 2023 | Rexulti, Jynarque |
| Sk Life Science, INC. | $123.01 | 2022 | |
| Lilly USA, LLC | $122.53 | 2023 | Mounjaro |
| Abbvie INC. | $121.81 | 2023 | Avycaz |
| Janssen Pharmaceuticals, INC | $104.18 | 2021 | |
| Janssen Biotech, INC. | $98.62 | 2022-2023 | Tremfya, Simponi Aria |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $94.25 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $83.99 | 2023 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.95 | 2023 | Jardiance |
| Akebia Therapeutics INC | $63.67 | 2019-2024 | Vafseo |
| Ardelyx, INC. | $56.50 | 2024-2025 | Ibsrela |
| Vantive US Healthcare LLC | $50.00 | 2025 | Renal - Pd |
| Travere Therapeutics, INC. | $33.78 | 2024-2025 | Filspari |
| Baxter Healthcare | $27.50 | 2024 | Renal - Pd |
| Calliditas Therapeutics US INC. | $18.00 | 2025 | Tarpeyo |
| Ultragenyx Pharmaceutical INC. | $17.87 | 2023 | Crysvita |
| Arbor Pharmaceuticals, INC. | $16.58 | 2021 | |
| Fresenius USA Marketing, INC. | $14.55 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chetan Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.